Uma mistura fitoterápica Immunity-6™ inibe a ativação de células leucêmicas mielóides envolvendo sinalização purinérgica
Data
2023-06-07
Autores
Bella, Yanesko Fernandes 
Orientadores
Vieira, Rodolfo de Paula
Tipo
Dissertação de mestrado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
A leucemia está entre os tipos mais comuns de cânceres hematológicos e o uso de fitoterápicos para prevenir e tratar a leucemia está em rápido desenvolvimento. Entre várias vias moleculares envolvidas na patogênese e exacerbações da leucemia, a sinalização purinérgica se revela como um componente chave. No presente estudo, os efeitos de duas doses (5ug/mL e 10ug/mL) de Immunity-6™, um fitocomplexo composto por beta-glucana, chá verde (Camelia sinensis), camomila (Matricaria chamomilla) e ácido ascórbico ( vitamina C) foi testada in vitro, utilizando linhagem de células de leucemia mieloide crônica (K-562; 5×104/mL/poço), que foram desafiadas com lipopolissacarídeo (LPS; 1ug/mL) por 24 horas. Os resultados demonstraram que ambas as doses de Immunity-6™ inibiram a liberação de ATP (p<0,001) e o receptor P2X7 em níveis de expressão de mRNA (p<0,001). A inibição purinérgica pelo Immunity-6™ foi seguida pela redução da liberação das citocinas pró-inflamatórias IL-1beta (p<0,001) e IL-6 (p<0,001), enquanto apenas 5ug/mL de Immunity-6™ reduziu a liberação de TNF -alfa (p<0,001). Além de inibir a liberação de citocinas pró-inflamatórias, ambas as doses de Immunity-6™ induziram a liberação da citocina anti-inflamatória IL-10 (p<0,001), enquanto apenas a dose maior (10ug/mL) de Immunity-6™ induziu a liberação do antiinflamatório IL-1ra (p<0,05) e klotho (p<0,001). Assim, o Immunity-6™ pode ser um adjuvante promissor no tratamento da leucemia e outros ensaios clínicos são garantidos.
Leukemia is among the most common types of hematological cancers and the use of herbal medicines to prevent and treat leukemia are under quick development. Among several molecular pathways involved in leukemia pathogenesis and exacerbations, purinergic signaling is revealed as a key component. In the present study, the effects of two doses (5 ug/mL and 10 ug/mL) of Immunity-6™, a phytocomplex composed by beta-glucan, green tea (Camelia sinensis), chamomile (Matricaria chamomilla), and ascorbic acid (vitamin C) was tested in vitro, using chronic myelogenous leukemia cell line (K-562; 5 ×104/mL/well), which were challenged with lipopolysaccharide (LPS; 1 ug/mL) for 24 h. The results demonstrated that both doses of Immunity-6™ inhibited ATP release (p < 0.001) and P2×7 receptor at mRNA levels expression (p < 0.001). Purinergic inhibition by Immunity-6™ was followed by reduced release of proinflammatory cytokines IL-1beta (p < 0.001) and IL-6 (p < 0.001), while only 5 ug/mL of Immunity-6™ reduced the release of TNF-alpha (p < 0.001). Beyond to inhibit the release of pro-inflammatory cytokines, both doses of Immunity-6™ induced the release of anti-inflammatory cytokine IL-10 (p < 0.001), while only the higher dose (10 ug/mL) of Immunity-6™ induced the release of anti-inflammatory IL-1ra (p < 0.05) and klotho (p < 0.001). Thus, Immunity-6™ may be a promising adjuvant in the treatment of leukemia and further clinical trials are guaranteed.
Leukemia is among the most common types of hematological cancers and the use of herbal medicines to prevent and treat leukemia are under quick development. Among several molecular pathways involved in leukemia pathogenesis and exacerbations, purinergic signaling is revealed as a key component. In the present study, the effects of two doses (5 ug/mL and 10 ug/mL) of Immunity-6™, a phytocomplex composed by beta-glucan, green tea (Camelia sinensis), chamomile (Matricaria chamomilla), and ascorbic acid (vitamin C) was tested in vitro, using chronic myelogenous leukemia cell line (K-562; 5 ×104/mL/well), which were challenged with lipopolysaccharide (LPS; 1 ug/mL) for 24 h. The results demonstrated that both doses of Immunity-6™ inhibited ATP release (p < 0.001) and P2×7 receptor at mRNA levels expression (p < 0.001). Purinergic inhibition by Immunity-6™ was followed by reduced release of proinflammatory cytokines IL-1beta (p < 0.001) and IL-6 (p < 0.001), while only 5 ug/mL of Immunity-6™ reduced the release of TNF-alpha (p < 0.001). Beyond to inhibit the release of pro-inflammatory cytokines, both doses of Immunity-6™ induced the release of anti-inflammatory cytokine IL-10 (p < 0.001), while only the higher dose (10 ug/mL) of Immunity-6™ induced the release of anti-inflammatory IL-1ra (p < 0.05) and klotho (p < 0.001). Thus, Immunity-6™ may be a promising adjuvant in the treatment of leukemia and further clinical trials are guaranteed.
Descrição
Citação
BELLA, Yanesko. Uma mistura fitoterápica Immunity-6™ inibe a ativação de células leucêmicas mielóides envolvendo sinalização purinérgica. 2023. 46 f. Dissertação (Mestrado em Ciências do Movimento Humano e Reabilitação) - Instituto de Saúde e Sociedade, Universidade Federal de São Paulo, Santos, 2023.